GTCR and Maravai Complete Strategic Equity Investment in Vector Laboratories

GTCR, a leading private equity firm, today announced that it has completed a strategic equity investment in Vector Laboratories, Inc. ("Vector" or the "Company"), through GTCR’s previously established Maravai LifeSciences ("Maravai") management partnership with CEO Carl Hull.  Vector is a leading provider of life science products, including labeling and detection reagents, that help medical and scientific researchers visualize cells in experiments which are central to the understanding of cancer and other diseases. 

Read More
walter Lentfertmaravai
GTCR Announces Partnership with Carl Hull and Eric Tardif to Form Maravai Life Sciences

Chicago, IL, GTCR, a leading private equity firm, today announced that it has entered into a partnership with Carl Hull and Eric Tardif to form Maravai LifeSciences, Inc. (“Maravai”). The new company, headquartered in San Diego, California, will focus on acquiring companies and products in the diagnostics and life sciences industry as part of a strategy to build a market leading healthcare business. GTCR will invest up to $300 million of equity capital to support management’s strategy.

Read More
walter Lentfert